Table 2.
Grading the evidence with GRADEpro guideline development tool.
| Certainty assessment | No. of patients | Effect | Certainty | Importance | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Baricitinib | Control | Relative (95% CI) | Absolute (95% CI) | ||
| Mortality (4 RCTs) | ||||||||||||
|
| ||||||||||||
| 4 | Randomised trials | Seriousa | Not serious | Not serious | Not serious | None | 619/5478 (11.3%) | 712/5337 (13.3%) | RR 0.74 (0.58 to 0.94) | 35 fewer per 1,000 (from 56 fewer to 8 fewer) |
⊕⊕⊕ ◯
Moderate |
Critical |
| Disease progression (3 RCTs) | ||||||||||||
|
| ||||||||||||
| 3 | Randomised trials | Seriousa | Not serious | Not serious | Not serious | None | 454/5239 (8.7%) | 528/5113 (10.3%) | RR 0.84 (0.75 to 0.95) | 17 fewer per 1,000 (from 26 fewer to 5 fewer) |
⊕⊕⊕ ◯
Moderate |
Critical |
CI: confidence interval; RR: risk ratio. aOpen-label study [12].